BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//MedNet - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://mednetus.net
X-WR-CALDESC:Events for MedNet
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20240310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20241103T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20250620T080000
DTEND;TZID=America/New_York:20250620T170000
DTSTAMP:20260423T064237
CREATED:20250620T072436Z
LAST-MODIFIED:20250620T072436Z
UID:10000014-1750406400-1750438800@mednetus.net
SUMMARY:Advances in the Understanding of Etiology\, Evaluation\, and Management of Neurotrophic Keratitis
DESCRIPTION:March 1\, 2025 \nTake Me to the Event Registration \nEVENT Summary \nDates \nSaturday\, March 1\, 2025\, 10:00 AM ET\, 9:00 AM CT\, 8:00 AM MT\, and 7:00 AM PT \nLocation \nVirtual \nTarget Audience \nOphthalmologists\, optometrists\, and advanced practice providers (physician assistants and nurse practitioners) who manage patients with neurotrophic keratitis \nFormat \nZoom Webinar \nCredits \n1.25 / AMA PRA Category 1 Credit(s)TM\n1.25 / COPE CE Credits \nCost \nFree \n\n\n\n\n\n\n\n\nProgram Description \nClick to Go to the Event Registration \nThe activity will focus on: \nEtiology \n\nDamage at any level to the fifth cranial nerve\, from the trigeminal nucleus to the corneal nerve endings\, may lead to the development of NK.\nSystemic diseases that may compromise trigeminal function\, such as diabetes\, multiple sclerosis\, and Leprosy\, may lead to the development of NK.\nWound healing after anterior segment surgery or trauma.\n\nPathophysiology \n\nCorneal nerves maintain corneal epithelial integrity\, proliferation\, and wound healing.\nIt has been postulated that corneal sensory nerve damage leads to marked changes in levels of neuromodulators that cause impairment in epithelial cell vitality and metabolism of the epithelial cells.\n\nEvaluation – The hallmark of NK is reduced or absent corneal sensation \n\nCochet-Bonnet or no-contact gas esthesiometer\nSlit lamp examination\nDilated fundus examination\n\nStaging – NK can be classified into three stages according to the Mackie classification. \n\nStage 1 – corneal epithelial changes with dry and cloudy epithelium\, superficial punctate keratopathy\, and corneal edema.\nStage 2 – recurrent and/or persistent epithelial defects with an oval or circular shape\, most frequently localized at the superior half of the cornea.\nStage 3 – corneal ulcer with stromal involvement that may be complicated by stromal melting and progression to corneal perforation.\n\nTreatment of NK – Treatment of NK depends on disease severity. \n\nTopical cenegermin – Cenegermin is currently the only medication approved for treating NK; it is approved for all stages.\n\nOther Treatment Options \n\nAntibiotics\nAutologous Serum Drops\nContact Lenses – Bandage contact lenses\, Scleral lenses\nTarsorrhaphy – Eyelids are partially or completely closed to protect the cornea and preserve tear fluid\, which is used to heal corneal ulcers\n\nAgenda \n\nOverview of the etiology\, pathophysiology\, recommended screening\, and testing procedures used in diagnosing NK – Walter Whitley\, OD\nDiscuss the efficacy and clinical utility of current and emerging treatments for early- and late-stage NK – Stephen C. Pflugfelder\, MD\n\nIntended Audience \nOphthalmologists\, optometrists\, and advanced practice providers (physician assistants and nurse practitioners) who manage patients with neurotrophic keratitis \nCommercial Supporter \nSupported by an unrestricted educational grant from Dompé US Inc. \nLearning Objectives \n\nSummarize the etiology\, pathophysiology\, recommended screening\, and testing procedures used to establish a diagnosis of NK\nAssess the efficacy and clinical utility of current and emerging treatments for the early- and late-stage NK\n\nAccredited Providers \nAmedco and MedNet have collaborated to design and execute this activity. \n       \nJoint Accreditation Statement \nIn support of improving patient care\, this activity has been planned and implemented by Amedco LLC and MedNet. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME)\, the Accreditation Council for Pharmacy Education (ACPE)\, and the American Nurses Credentialing Center (ANCC)\, to provide continuing education for the healthcare team. Amedco Joint Accreditation #4008163. \nPhysicians (ACCME) Credit Designation \nAmedco LLC designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. \nOptometrists Credit \nAmedco is accredited by COPE to provide continuing education to optometrists. \nAmedco designates this activity for a maximum of 1.25 COPE credit. \nAdditional Credit Information \nPhysician Assistants\nPAs may claim a maximum of 1.25 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society. \nNurse Practitioners\nThe American Association of Nurse Practitioners (AANP) recognizes the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC) as approved accreditors and allow reciprocity for AANPCP continuing education credit. 1.25 hours. \nDisclosures of Relationships With Ineligible Companies Policy \nIn accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education\, all faculty\, planning committee members\, and other individuals\, who are in a position to control content\, are required to disclose all relationships with ineligible companies* (commercial interests) within the last 24 months. All educational materials are reviewed for fair balance\, scientific objectivity\, and levels of evidence. The ACCME requires us to disqualify from involvement in the planning and implementation of accredited continuing education any individuals (1) who refuse to provide this information or (2) whose conflicts of interests cannot be mitigated. \nPlanners’ and Managers’ Disclosures \nAll relevant relationships have been reviewed and mitigated. \nOff-Label Disclosure Statement \nFaculty members are required to inform the audience when they are discussing off-label\, unapproved uses of devices and drugs. Physicians should consult full prescribing information before using any product mentioned during this educational activity. \n\nFaculty \n \nWalter Whitley\, OD\, MBA\, FAAO\nVirginia Eye Consultants\nNorfolk\, VA \n \nStephen C. Pflugfelder\, MD\nProfessor and James and Margaret Elkins Chair in Ophthalmology\nBaylor College of Medicine\nHouston\, TX \nInstructions/Technical Requirements \nHardware: An internet-enabled computer\, smartphone\, tablet\, or other mobile device with audio and internet capabilities. \nSoftware: Installation of software like GoToWebinar may be necessary. \nCost \nThere are no fees for participating and receiving CME and COPE credit for this activity. \nContact \nBrian Waggoner\nProgram Manager\nMedNet\nbrianw@mmhus.net
URL:https://mednetus.net/event/advances-in-the-understanding-of-etiology-evaluation-and-management-of-neurotrophic-keratitis-2/
CATEGORIES:Live Program
ATTACH;FMTTYPE=image/jpeg:https://mednetus.net/wp-content/uploads/2025/06/q1gr1slaec0j-NK800x450.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20250719T080000
DTEND;TZID=America/New_York:20250719T170000
DTSTAMP:20260423T064237
CREATED:20250620T065419Z
LAST-MODIFIED:20250620T065419Z
UID:10000011-1752912000-1752944400@mednetus.net
SUMMARY:New Paradigms in the Management of Hereditary Transthyretin Amyloidosis Mixed Phenotype (ATTRv): ATTRv-CM and ATTRv-PN
DESCRIPTION:July 19\, 2025 \nTake Me to the Event Registration\n\n\nEVENT Summary \nDates \nSaturday\, July 19\, 2025\, 10:00 AM ET\, 9:00 AM CT\, 8:00 AM MT\, and 7:00 AM PT \nLocation \nVirtual \nTarget Audience \nCardiologists\, neurologists\, geneticists\, radiologists\, primary care physicians\, nurse practitioners\, physician assistants\, and nurses who diagnose and treat patients with hereditary transthyretin amyloidosis \nFormat \nZoom Webinar \nCredits \n1.25 / AMA PRA Category 1 CreditsTM\n1.25 / ANCC Contact Hours \nCost \nFree \n\nProgram Description \nWebinar Registration – ZoomTake Me to the Event Registration \nThis program will provide up-to-date\, evidence-based information for diagnosing and managing ATTR-CM and ATTR-PN patients. The activity will focus on: \n\nATTR-CM and ATTR-PN – Frequency and characteristics of ATTR-CM and ATTR-PN\nDiagnosis of ATTR-CM\n\nNuclear scintigraphy (including Tc99m PYP\, Tc-99m DPD\, and Tc-99m HDMP)\nCardiovascular magnetic resonance (CMR)\nEchocardiography\nMagnetic resonance imaging (MRI)\nWestern blot assay\n\n\nDiagnosis of ATTR-PN\n\nScreening laboratory tests include blood glucose evaluations\, serum free light chain (FLC) serum B12 with metabolites\, and serum and urine immunofixation electrophoresis.\nTTR gene sequencing\, looking for TTR gene amyloidogenic variants\, and tools for detecting amyloid deposits.\nHistological documentation of amyloid in diagnosing ATTR.\nCongo red staining with apple green birefringence under polarized light represents the pathognomonic appearance of amyloid.\nSural nerve biopsy for confirming ATTRv-PN\, with a sensitivity of up to 86%.\nTarget organ biopsy offers the highest diagnostic yield; less invasive methods like abdominal fat aspiration or salivary gland biopsy are viable alternatives.\n\n\nTreatment of ATTR-CM and ATTR-PN- Novel treatment options for ATTR-CM and ATTR-PN\n\nTetramer stabilizers – Acoramidis\, Tafamidis\n\nAcoramidis\, FDA accepted the New Drug Application (NDA) on February 5\, 2024\, as an oral treatment for ATTR-CM.\nTafamidis is FDA-approved for treating wild-type ATTR (ATTRwt) and hereditary ATTR (ATTRv) cardiomyopathy.\n\n\nAntisense oligonucleotides – Eplontersen\, Inotersen\n\nEplontersen FDA accepted Fast track designation on Feb 8\, 2024\, for ATTR-CM\, and in December 2023\, eplontersen was approved for the treatment of ATTR-PN\nInotersen was FDA-approved for the treatment of ATTR-PN\n\n\nSmall interfering RNAs – Patisiran\, Vutrisiran\n\nPatisiran is approved for the treatment of ATTR-PN\nVutrisiran is approved for both the ATTR-CM and ATTR-PN\n\n\nNonsteroidal anti-inflammatory drug – Diflunisal\nInvestigational therapies include a TTR stabilizer\, AG10; 2 antifibril agents\, PRX004 and doxycycline/tauroursodeoxycholic acid; and 2 gene silencers\, vutrisiran and AKCEA-TTR-LRx; and clinical trials are ongoing.\n\n\n\nAgenda \n• Discuss the diagnosis and novel treatment options for ATTR-CM – Michelle Kittleson\, MD\, PhD \n• Discuss the diagnosis and novel treatment options for ATTR-PN – Chafic Karam\, MD \nIntended Audience \nCardiologists\, neurologists\, geneticists\, radiologists\, primary care physicians\, nurse practitioners\, physician assistants\, and nurses who diagnose and treat patients with hereditary transthyretin amyloidosis (ATTRv;v for variant)\, ATTR-CM and ATTR-PN. \nCommercial Supporter \nSupported by a restricted educational grant from Alnylam U.S.\, Inc. \nLearning Objectives \n\nSummarize the characteristics\, related disabilities\, comorbidities\, and variable disease presentations and course of hereditary transthyretin amyloidosis mixed phenotype\nAppraise nuclear scintigraphy’s role (including Tc99m PYP\, Tc-99m DPD\, and Tc-99m HDMP)\, genetic testing in diagnosing patients with suspected ATTR-CM and ATTR-PN\nIdentify novel treatment options for ATTR-CM and ATTR-PN with tetramer stabilizers\, antisense oligonucleotides\, and small interfering RNAs\nImplement interdisciplinary care for patients with ATTR-CM and ATTR-PN\, incorporating primary and specialty care\, supportive ancillary services\, and shared decision-making.\n\nAccredited Providers \nJointly Accredited by Haymarket Medical Education and MedNet \n   \nJoint Accreditation Statement \nIn support of improving patient care\, this activity has been planned and implemented by Haymarket Medical Education and MedNet. Haymarket Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME)\, the Accreditation Council for Pharmacy Education (ACPE)\, and the American Nurses Credentialing Center (ANCC)\, to provide continuing education for the healthcare team. Haymarket Medical Education Joint Accreditation #JA4008232. \nPhysicians (ACCME) Credit Designation \nHaymarket Medical Education designates this live activity for a maximum of 1.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. \nNurses \nThis activity is awarded 1.25 contact hours (based on 60 minutes per contact hour). \nAdditional Credit Information \nPhysician Assistants\nPAs may claim a maximum of 1.25 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society. \nNurse Practitioners\nThe American Association of Nurse Practitioners (AANP) recognizes the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC) as approved accreditors and allows reciprocity for AANPCP continuing education credit. 1.25 hours. \nDisclosures of Relationships with Ineligible Companies Policy \nIn accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education\, all faculty\, planning committee members\, and other individuals\, who are in a position to control content\, are required to disclose all relationships with ineligible companies* (commercial interests) within the last 24 months. All educational materials are reviewed for fair balance\, scientific objectivity\, and levels of evidence. The ACCME requires us to disqualify from involvement in the planning and implementation of accredited continuing education any individuals (1) who refuse to provide this information or (2) whose conflicts of interests cannot be mitigated. \nPlanners’ and Managers’ Disclosures \nAll relevant relationships have been reviewed and mitigated. \nOff-Label Disclosure Statement \nFaculty members are required to inform the audience when they are discussing off-label\, unapproved uses of devices and drugs. Physicians should consult full prescribing information before using any product mentioned during this educational activity. \nFaculty \n \nMichelle M. Kittleson\, M.D.\, Ph.D.\nDirector of Education in Heart Failure and Transplantation\nProfessor of Medicine\nSmidt Heart Institute\, Cedars-Sinai\nLos Angeles\, CA \nDr. Kittleson has no relevant financial relationships with ineligible companies to disclose. \n \nChafic Karam\, MD\nProfessor of Clinical Neurology\nChief\, Neuromuscular Division\nDirector\, Neuromuscular Fellowship\nDepartment of Neurology\nUniversity of Pennsylvania\nPhiladelphia\, PA \nDr. Karam reports the following relevant financial relationships with ineligible companies to disclose:\nConsultant: Alnylam\, AstraZeneca\, Novo Nordisk\, Alexion\, Corino\, and Pfizer\nResearch Support: Ionis \nInstructions/Technical Requirements \nHardware: An internet-enabled computer\, smartphone\, tablet\, or other mobile device with audio and internet capabilities. \nSoftware: Installation of software like Zoom may be necessary. \nCost \nThere are no fees for participating and receiving CME and CE credit for this activity. \nContact \nBrian Waggoner\nProgram Manager\nMedNet\nbrianw@mmhus.net
URL:https://mednetus.net/event/new-paradigms-in-the-management-of-hereditary-transthyretin-amyloidosis-mixed-phenotype-attrv-attrv-cm-and-attrv-pn/
CATEGORIES:Live Program
ATTACH;FMTTYPE=image/jpeg:https://mednetus.net/wp-content/uploads/2025/06/n81qh2gf0iyb-ATTRvLive800x450.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251115T082500
DTEND;TZID=America/New_York:20251115T123000
DTSTAMP:20260423T064237
CREATED:20250815T162214Z
LAST-MODIFIED:20251103T191354Z
UID:10000021-1763195100-1763209800@mednetus.net
SUMMARY:Changing Landscape of Management in Eye Diseases: Glaucoma\, Ocular Surface Disease\, Neurotrophic Keratitis\, Cataract Surgery\, and Vitreoretinal Surgery
DESCRIPTION:
URL:https://mednetus.net/event/changing-landscape-of-management-in-eye-diseases-glaucoma-ocular-surface-disease-neurotrophic-keratitis-cataract-surgery-and-vitreoretinal-surgery/
LOCATION:Zoom Live Webinar\, United States
CATEGORIES:Live Program
END:VEVENT
END:VCALENDAR